Structure Therapeutics Q2 net loss widens to $106.2 million; Phase 3 dosing begins
Structure Therapeutics reported second quarter 2026 results, with a net loss of $106.2 million, up from $61.7 million a year earlier, as research and development expenses rose to $100.1 million from $54.7 million. The company said it has begun dosing patients in its Phase 3 ACCOMPLISH program for aleniglipron and expects its $1.3 billion in cash and short-term investments to fund operations and key clinical milestones through 2028.
Key points
- Q2 2026 net loss of $106.2 million vs. $61.7 million in Q2 2025; share-based compensation of $12.6 million included
- R&D expenses of $100.1 million vs. $54.7 million; G&A expenses of $18.6 million vs. $15.7 million
- Cash, cash equivalents and short-term investments of $1.3 billion at June 30, 2026, down from $1.5 billion at March 31, 2026
- John Berrios appointed Chief Commercial Officer; first patients dosed in Phase 3 ACCOMPLISH-1 and -2 trials
The filing
Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.